Valcyte—prescribed for over a decade in the prevention of cytomegalovirus
disease in high-risk (D+/R-)* adult and pediatric transplant patients†
- Indicated for multiple organs
- Available in two formulations:
- Valcyte tablets are available for adult kidney, heart, and kidney-pancreas transplant patients
- Valcyte oral solution (OS) and tablets are available for pediatric kidney and heart transplant patients
- *Donor CMV seropositive/Recipient CMV seronegative (D+/R-).
- †IMS Health Monthly NPA Prescription Data (2001-April 2013).
Valcyte® (valganciclovir hydrochloride) is a cytomegalovirus (CMV) nucleoside analogue DNA polymerase inhibitor indicated in adult patients for the prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R−]), and for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).1
Valcyte is indicated in pediatric patients for the prevention of CMV disease in kidney or heart transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R−]).1
For each of these Valcyte patient populations, learn about:
- Bioavailability and Pharmacokinetics
- Drug Interactions
- Drug Formulation
- Valcyte for Adult Solid Organ Transplant Patients
Learn about Valcyte and high-risk D+/R– adult kidney, heart, or kidney-pancreas transplant patients.
- Valcyte for Pediatric Transplant Patients
Find out about Valcyte and high-risk pediatric kidney or heart transplant patients.
- Valcyte for AIDS Patients
Learn about Valcyte and AIDS patients with CMV retinitis.